Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + Toripalimab Maintenance in Metastatic NPC
NCT05484375Phase 2Not yet recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Sep 2022
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of toripalimab, capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Cancer Center of Guangzhou Medical University. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
toripalimabcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05484375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05484375.